FDA Advisory Committee Backs Merck’s Vorapaxar

by Kathy Jones on  January 16, 2014 at 11:12 PM Drug News
RSS Email Print This Page Comment bookmark
Font : A-A+

Merck's anti-platelet drug vorapaxar has received backing from an FDA advisory committee who voted in favor of approving the drug for reducing atherothrombotic events in patients who have a history of myocardial infarction (MI).
 FDA Advisory Committee Backs Merck’s Vorapaxar
FDA Advisory Committee Backs Merck’s Vorapaxar

The Cardiovascular and Renal Drugs Advisory Committee of the FDA voted 10-1 in favor of approving the drug with the members stating that the benefits of the drug far outweighed the risks. The vote comes just after the release of FDA review documents which declared the drug to be effective in patients with history of MI.

The drug has been found to cause bleeding in some patients and the lone member of the committee who voted against the approval recommendation, Mori Krantz, said that apart from bleeding, he was also not sure how many patients will actually benefit from the drug.

"I voted No, not because I didn't think the primary efficacy was met, but I worried about the size of the benefit and, in particular, with endpoints that were harder, such as cardiovascular death, where we'd need to treat nearly a thousand patients to have one person benefit", Krantz said.



Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive

Loading...